Product Information
MOTPOLY XR 150 MG CAPSULE is a brand product labeled by Aucta Pharmaceuticals, Inc., priced at $21.5019 per EA under NDC 73289006402. Its NADAC has been published 42 times since Dec 17, 2025.
FDA first approved this application on May 4, 2023.
The High Outlier badge above means this manufacturer's average price in the lacosamide market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
150 mg/1
Manufacturer
Aucta Pharmaceuticals, Inc.NDC
73289006402
Classification
Brand
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
7/1/2026
Active Ingredients
LACOSAMIDEApproval Type
New Drug (NDA)
FDA Application
NDA216185FDA Approved
5/4/2023
On Market Since
5/5/2023
Pharmacological Classes
Price Statistics
The NADAC for MOTPOLY XR 150 MG CAPSULE has been published 42 times since Dec 17, 2025, and over the history we have for it it has risen 3.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $21.5019 per EA |
|---|---|
| All-time high | $21.5019 (Sep 30, 2026) |
| All-time low | $20.6881 (Dec 17, 2025) |
| 52-week high | $21.5019 |
| 52-week low | $20.6881 |
| Median price | $21.3116 |
| Average price | $21.3082 |
| Largest weekly change | +3.0% (Jan 14, 2026) |
| Weeks tracked | 42 |
| Tracking since | Dec 17, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the lacosamide market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aucta Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
lacosamide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MOTPOLY XR 150 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for MOTPOLY XR 150 MG CAPSULE, manufactured by Aucta Pharmaceuticals, Inc., is $21.5019 per EA (NDC 73289006402), effective Sep 30, 2026.
How has the price of MOTPOLY XR 150 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for MOTPOLY XR 150 MG CAPSULE has risen 3.9%. It has been tracked across 42 weekly CMS publications since Dec 17, 2025.
What are the highest and lowest recorded NADAC prices for MOTPOLY XR 150 MG CAPSULE?
Since Dec 17, 2025, the NADAC for MOTPOLY XR 150 MG CAPSULE has ranged from a low of $20.6881 (Dec 17, 2025) to a high of $21.5019 (Sep 30, 2026), with a median of $21.3116 per EA.
Are there cheaper alternatives to MOTPOLY XR 150 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of MOTPOLY XR 150 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures MOTPOLY XR 150 MG CAPSULE?
MOTPOLY XR 150 MG CAPSULE (NDC 73289006402) is labeled by Aucta Pharmaceuticals, Inc., and CMS classifies it as a brand product.